Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1152 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Olorofim for invasive fungal infections	Olorofim	Fungal infections	Infectious Disease	2023	View \| Download
Omalizumab biosimilar for treating chronic spontaneous urticaria	Omalizumab biosimilar	Chronic spontaneous urticaria (CSU)	Dermatology	2023	View \| Download
Omalizumab for chronic rhinosinusitis with nasal polyps	Omalizumab (Xolair)	Rhinosinusitis	Ear Nose and Throat (ENT)	2019	View \| Download
Omaveloxolone for the treatment of Friedreich's ataxia	Omaveloxolone	Friedreich's ataxia	Genetic Disorders , Neurology	2023	View \| Download
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction	Omecamtiv Mecarbil (AMG 423; CK-1827452)	Heart failure (HF)	Cardiovascular System	2020	View \| Download
Ondansetron for treating alcohol use disorder	Ondansetron (Setrodon;TO-2061;AD04)	Alcohol use disorder	Mental and Behavioural Health	2023	View \| Download
Onfekafusp alfa in addition to doxorubicin for advanced or metastatic soft tissue sarcoma – first line	Doxorubicin (Livatag; BA-003; Caelyx; Sarcodoxome; SP-1049C; Resmycin; JNS002; doxorubicin hydrochloride) , Onfekafusp alfa (L19-TNF; Fibromun)	Soft tissue sarcoma	Sarcoma	2019	View \| Download
ONS-5010 for neovascular age-related macular degeneration	ONS-5010	Neovascular age-related macular degeneration	Ophthalmology	2022	View \| Download
Opicapone adjuvant for the treatment of idiopathic Parkinson's disease	Opicapone (Ongentys)	Parkinson's disease	Neurology	2023	View \| Download
Oportuzumab monatox for non-muscle invasive bladder cancer - second line	Oportuzumab monatox (Vicinium; VB4-845; Proxinium)	Bladder cancer	Urological Cancer	2020	View \| Download